Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

This study is testing a T-cell engaging treatment strategy to eliminate minimal residual disease (tiny amounts of cancer remaining after stem cell transplant) in newly diagnosed multiple myeloma patients who still have detectable cancer cells despite initial treatment and transplant. **You may be eligible if...** - You are 18 or older - You were recently diagnosed with multiple myeloma, received at least 4 cycles of induction therapy with an anti-CD38 antibody-based regimen, and underwent a stem cell transplant within the last 60–120 days - Sensitive genetic testing (NGS) still detects cancer cells at a level of at least 1 in 100,000 - You had at least a partial response to treatment - You have adequate blood counts and organ function **You may NOT be eligible if...** - Your multiple myeloma is progressing - You have very poor organ function or significant bone marrow failure Talk to your doctor to see if this trial is right for you.